Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 7.13% and Operating profit at -19.34% over the last 5 years
2
The company has declared positive results in Mar'2025 after 9 consecutive negative quarters
3
With ROE of 1.92%, it has a very expensive valuation with a 3.22 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,982 Million (Mid Cap)
167.00
NA
0.01%
-0.24
2.63%
3.36
Revenue and Profits:
Net Sales:
124 Million
(Quarterly Results - Mar 2026)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.81%
0%
-11.81%
6 Months
-3.49%
0%
-3.49%
1 Year
-3.54%
0%
-3.54%
2 Years
4.54%
0%
4.54%
3 Years
-36.61%
0%
-36.61%
4 Years
0%
0%
0.0%
5 Years
-38.33%
0%
-38.33%
Shanghai Sanyou Medical Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.13%
EBIT Growth (5y)
-19.34%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.24
Tax Ratio
26.42%
Dividend Payout Ratio
7.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.81%
ROE (avg)
6.42%
Valuation key factors
Factor
Value
P/E Ratio
167
Industry P/E
Price to Book Value
3.22
EV to EBIT
249.95
EV to EBITDA
71.04
EV to Capital Employed
4.25
EV to Sales
12.30
PEG Ratio
5.02
Dividend Yield
0.01%
ROCE (Latest)
1.70%
ROE (Latest)
1.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
123.60
151.30
-18.31%
Operating Profit (PBDIT) excl Other Income
1.20
2.60
-53.85%
Interest
3.40
0.30
1,033.33%
Exceptional Items
4.10
1.10
272.73%
Consolidate Net Profit
2.10
-9.20
122.83%
Operating Profit Margin (Excl OI)
9.50%
-80.70%
9.02%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -18.31% vs 6.77% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 122.83% vs -141.44% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
539.00
450.50
19.64%
Operating Profit (PBDIT) excl Other Income
109.80
67.30
63.15%
Interest
3.10
2.50
24.00%
Exceptional Items
-12.80
-6.00
-113.33%
Consolidate Net Profit
44.90
12.10
271.07%
Operating Profit Margin (Excl OI)
93.00%
13.10%
7.99%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 19.64% vs -1.36% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 271.07% vs -89.35% in Dec 2024
About Shanghai Sanyou Medical Co. Ltd. 
Shanghai Sanyou Medical Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






